Methadone in post-herpetic neuralgia: A pilot proof-of-concept study

Detalhes bibliográficos
Autor(a) principal: Teixeira, Manoel J.
Data de Publicação: 2013
Outros Autores: Okada, Massako, Moscoso, Ana Sofia Cueva, Puerta, Mariana Yumi Takahashi, Yeng, Lin T., Galhardoni, Ricardo, Tengan, Sergio, de Andrade, Daniel Ciampi
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/76938
Resumo: OBJECTIVE: This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens. METHODS: This cross-over study was double blind and placebo controlled. Ten opioid naïve post-herpetic neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical evaluations were performed four times (before and after each three-week treatment period). The evaluations included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse events profile, and evoked pain assessment. All patients provided written informed consent before being included in the study. ClinicalTrials.gov: NCT01752699 RESULTS: Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain, as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone treatment, none after the placebo, p = 0.031). Evoked pain was reduced under methadone compared to placebo (50% improved after the methadone treatment, none after the placebo, p = 0.031). Allodynia reduction correlated with sleep improvement (r = 0.67, p = 0.030) during the methadone treatment. The side effects profile was similar between both treatments. Conclusions: Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an adjunctive treatment for post-herpetic neuralgia in larger prospective studies.
id USP-19_843eb8ccee8dbb3be04a7db620ca0558
oai_identifier_str oai:revistas.usp.br:article/76938
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Methadone in post-herpetic neuralgia: A pilot proof-of-concept studyOBJECTIVE: This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens. METHODS: This cross-over study was double blind and placebo controlled. Ten opioid naïve post-herpetic neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical evaluations were performed four times (before and after each three-week treatment period). The evaluations included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse events profile, and evoked pain assessment. All patients provided written informed consent before being included in the study. ClinicalTrials.gov: NCT01752699 RESULTS: Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain, as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone treatment, none after the placebo, p = 0.031). Evoked pain was reduced under methadone compared to placebo (50% improved after the methadone treatment, none after the placebo, p = 0.031). Allodynia reduction correlated with sleep improvement (r = 0.67, p = 0.030) during the methadone treatment. The side effects profile was similar between both treatments. Conclusions: Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an adjunctive treatment for post-herpetic neuralgia in larger prospective studies.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2013-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/7693810.1590/clin.v68i7.76938Clinics; Vol. 68 No. 7 (2013); 1057-1060Clinics; v. 68 n. 7 (2013); 1057-1060Clinics; Vol. 68 Núm. 7 (2013); 1057-10601980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/76938/80799Teixeira, Manoel J.Okada, MassakoMoscoso, Ana Sofia CuevaPuerta, Mariana Yumi TakahashiYeng, Lin T.Galhardoni, RicardoTengan, Sergiode Andrade, Daniel Ciampiinfo:eu-repo/semantics/openAccess2014-03-24T11:50:37Zoai:revistas.usp.br:article/76938Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2014-03-24T11:50:37Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
spellingShingle Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
Teixeira, Manoel J.
title_short Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title_full Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title_fullStr Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title_full_unstemmed Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title_sort Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
author Teixeira, Manoel J.
author_facet Teixeira, Manoel J.
Okada, Massako
Moscoso, Ana Sofia Cueva
Puerta, Mariana Yumi Takahashi
Yeng, Lin T.
Galhardoni, Ricardo
Tengan, Sergio
de Andrade, Daniel Ciampi
author_role author
author2 Okada, Massako
Moscoso, Ana Sofia Cueva
Puerta, Mariana Yumi Takahashi
Yeng, Lin T.
Galhardoni, Ricardo
Tengan, Sergio
de Andrade, Daniel Ciampi
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Teixeira, Manoel J.
Okada, Massako
Moscoso, Ana Sofia Cueva
Puerta, Mariana Yumi Takahashi
Yeng, Lin T.
Galhardoni, Ricardo
Tengan, Sergio
de Andrade, Daniel Ciampi
description OBJECTIVE: This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens. METHODS: This cross-over study was double blind and placebo controlled. Ten opioid naïve post-herpetic neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical evaluations were performed four times (before and after each three-week treatment period). The evaluations included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse events profile, and evoked pain assessment. All patients provided written informed consent before being included in the study. ClinicalTrials.gov: NCT01752699 RESULTS: Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain, as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone treatment, none after the placebo, p = 0.031). Evoked pain was reduced under methadone compared to placebo (50% improved after the methadone treatment, none after the placebo, p = 0.031). Allodynia reduction correlated with sleep improvement (r = 0.67, p = 0.030) during the methadone treatment. The side effects profile was similar between both treatments. Conclusions: Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an adjunctive treatment for post-herpetic neuralgia in larger prospective studies.
publishDate 2013
dc.date.none.fl_str_mv 2013-07-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/76938
10.1590/clin.v68i7.76938
url https://www.revistas.usp.br/clinics/article/view/76938
identifier_str_mv 10.1590/clin.v68i7.76938
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/76938/80799
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 68 No. 7 (2013); 1057-1060
Clinics; v. 68 n. 7 (2013); 1057-1060
Clinics; Vol. 68 Núm. 7 (2013); 1057-1060
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222760278949888